Table 1.
Baseline characteristics of PFIC patients with prognostic groups in pruritus response under MRX treatment *.
| Characteristics | All | Pruritus Responder | Pruritus Non-Responder |
|---|---|---|---|
| Number of participants | 19 | 11 | 8 |
| Age (at enrollment), y, median (IQR) | 3 (1.5, 4.5) | 3.0 (1, 4.5) | 3.5 (2.8, 5.5) |
| Female No. (%) | 68 | 73 | 63 |
| Pruritus score, median (IQR) | 1.9 (1.9, 2.1) | 2.5 (1.9, 3.0) | 1.9 (1.5,2.0) |
| Mutation | Mild/Moderate (7/12) | Mild/Moderate (4/7) | Mild/Moderate (3/5) |
| Total BA (µM), median (IQR) | 423 (286, 478) | 423 (238, 440) | 437 (303, 501) |
| 7α-C4 (ng/mL), median (IQR) | 2.3 (1.1, 3.8) | 1.9 (1.1, 4.8) | 2.5 (2.0,3.0) |
| FGF 19 (pg/mL), median (IQR) | 181 (107, 810) | 116 (84,568) | 687 (171,993) |
| Urso supplement (n) | 19 | 11 | 8 |
* Difference in each characteristic was evaluated by Welch’s two-sample t test. p > 0.05 for all baseline characteristics between pruritus responders and pruritus non-responders.